📊 CRIS Key Takeaways
Is Curis Inc. (CRIS) a Good Investment?
Curis is a pre-revenue stage biotech company burning substantial cash with negative stockholders' equity of -$14.7M, indicating the company has consumed more capital than it has raised. With only $8.3M in revenue against -$26.9M net income and -$20.8M operating cash outflow, the company faces severe financial distress and imminent liquidity crisis at current burn rates.
Curis shows very weak fundamentals: revenue is small relative to its cost base, operating margin is deeply negative, and free cash flow burn remains severe. Financial health is strained by negative stockholders' equity, sub-1.0 liquidity ratios, and limited cash relative to ongoing losses, making the modest revenue growth insufficient to offset balance-sheet and funding risk.
Why Buy Curis Inc. Stock? CRIS Key Strengths
- Modest revenue growth of 8.8% YoY shows some commercialization progress
- Positive cash position of $9.1M provides short-term runway
- No long-term debt reduces financing burden and bankruptcy risk from creditors
- Revenue grew 8.8% year over year, indicating some top-line progress
- The company reports no long-term debt, reducing traditional leverage pressure
- Cash and equivalents of $9.05M provide some near-term operating flexibility
CRIS Stock Risks: Curis Inc. Investment Risks
- Negative stockholders' equity of -$14.7M indicates shareholders have negative claim on assets
- Severe cash burn of -$20.8M operating cash flow with only $9.1M cash remaining (4.3 months runway)
- Operating losses of -$25.3M dwarf minimal $8.3M revenue, indicating unprofitable operations
- Current ratio of 0.70x signals inability to cover short-term obligations
- Negative free cash flow of -$250.8% FCF margin indicates unsustainable business model
- Operating and net margins are extremely negative, showing an unsustainable cost structure
- Negative stockholders' equity and a 0.70x current ratio signal significant financial stress
- Operating cash outflow of $20.83M suggests a short cash runway and likely future financing need
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth trajectory and path to profitability timeline
- Changes in stockholders' equity and need for capital raises
- Quarterly operating cash burn versus cash balance
- Revenue growth relative to operating expense trend
Curis Inc. (CRIS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CRIS Profit Margin, ROE & Profitability Analysis
CRIS vs Healthcare Sector: How Curis Inc. Compares
How Curis Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Curis Inc. Stock Overvalued? CRIS Valuation Analysis 2026
Based on fundamental analysis, Curis Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Curis Inc. Balance Sheet: CRIS Debt, Cash & Liquidity
CRIS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Curis Inc.'s revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $-6.88 indicates the company is currently unprofitable.
CRIS Revenue Growth, EPS Growth & YoY Performance
CRIS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.9M | -$7.7M | $-0.49 |
| Q2 2025 | $2.5M | -$8.6M | $-0.68 |
| Q1 2025 | $2.1M | -$10.6M | $-1.25 |
| Q3 2024 | $2.8M | -$10.1M | $-1.70 |
| Q2 2024 | $2.2M | -$11.6M | $-2.03 |
| Q1 2024 | $2.1M | -$11.6M | $-2.05 |
| Q3 2023 | $2.8M | -$11.6M | $-2.13 |
| Q2 2023 | $2.2M | -$11.6M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Curis Inc. Dividends, Buybacks & Capital Allocation
CRIS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Curis Inc. (CIK: 0001108205)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRIS
What is the AI rating for CRIS?
Curis Inc. (CRIS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRIS's key strengths?
Claude: Modest revenue growth of 8.8% YoY shows some commercialization progress. Positive cash position of $9.1M provides short-term runway. ChatGPT: Revenue grew 8.8% year over year, indicating some top-line progress. The company reports no long-term debt, reducing traditional leverage pressure.
What are the risks of investing in CRIS?
Claude: Negative stockholders' equity of -$14.7M indicates shareholders have negative claim on assets. Severe cash burn of -$20.8M operating cash flow with only $9.1M cash remaining (4.3 months runway). ChatGPT: Operating and net margins are extremely negative, showing an unsustainable cost structure. Negative stockholders' equity and a 0.70x current ratio signal significant financial stress.
What is CRIS's revenue and growth?
Curis Inc. reported revenue of $8.3M.
Does CRIS pay dividends?
Curis Inc. does not currently pay dividends.
Where can I find CRIS SEC filings?
Official SEC filings for Curis Inc. (CIK: 0001108205) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRIS's EPS?
Curis Inc. has a diluted EPS of $-2.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRIS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Curis Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRIS stock overvalued or undervalued?
Valuation metrics for CRIS: ROE of N/A (sector avg: 15%), net margin of -324.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRIS stock in 2026?
Our dual AI analysis gives Curis Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRIS's free cash flow?
Curis Inc.'s operating cash flow is $-20.8M, with capital expenditures of $0.0. FCF margin is -250.8%.
How does CRIS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -324.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.70 (avg: 2).